跳至主要内容
临床试验/RPCEC00000080
RPCEC00000080已完成4 期

Impact of Recombinant Human Erythropoietin(ior EPO-CIM)in oncology pediatric patients with post chemo and /or radiotherapy.

Center of Molecular Immunology(CIM)0 个研究点目标入组 161 人开始时间: 2009年7月3日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
161

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment

入排标准

年龄范围
1 years 至 18 years(—)
性别
All

入选标准

  • 1.Patients that fulfill with diagnostic criteria. 2.Patients with cytological and/or histological diagnosis of cancer of any localization that are receiving chemotherapy and/or radiotherapy. 3.Patients whose parents or tutors granted written consent for participation in the study. 4.Patients aged between 1 and 18 years.

排除标准

  • 1.Patients with known hypersensitivity to products derived from mammalian cells or hypersensitivity to human albumin. 2.Patients pregnant or breastfeeding. 3.Patients with active hemorrhage or hemolysis. 4.Patients with non-controlled arterial hypertension.

研究者

发起方
Center of Molecular Immunology(CIM)

相似试验